Skip to main content

Test Price

2,800 AED

โœ… Home Collection Available

ABCD1 Gene (X-Linked Adrenoleukodystrophy) โ€“ Genetic Test in UAE | 2,800 AED

Executive Summary & Core Metrics

This advanced genetic test detects pathogenic variants in the ABCD1 gene associated with X-linked adrenoleukodystrophy (X-ALD) using Next-Generation Sequencing (NGS). It delivers definitive diagnosis and carrier status determination with 99.9% diagnostic sensitivity, empowering families with precise genetic counseling. Processing is conducted in ISO 9001:2015 accredited laboratories. Paid VIP mobile phlebotomy and temperature-controlled cold-chain home collection are available daily from 8 AM to 11 PM.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Paid VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AMโ€“11 PM daily).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This test analyzes the ABCD1 gene using Next-Generation Sequencing (NGS) to detect pathogenic variants causing X-linked adrenoleukodystrophy (X-ALD), a severe peroxisomal disorder leading to neurological deterioration and adrenal insufficiency. The test provides definitive diagnosis and carrier status determination, empowering families with precise genetic counseling. Full gene coverage ensures detection of point mutations, small insertions/deletions, and large copy number variations.

Feature Our Test (NGS) Closest Alternative (Sanger Sequencing)
Precision99.9% Diagnostic Sensitivity>95% for known variants only
MethodologyNext-Generation Sequencing (NGS) โ€“ Full gene coverageTargeted Sanger sequencing of hotspot regions
Turnaround Time3โ€“4 Weeks4โ€“6 Weeks
Carrier DetectionComprehensive, including large deletions/duplicationsLimited to mostly known point mutations
Regulatory StatusDHAโ€“MOHAP Approved, ISO 9001:2015Variable

Physician Insight & Safety Protocols

โ€œGenetic testing for X-linked adrenoleukodystrophy using comprehensive NGS analysis provides invaluable clarity for families facing diagnostic uncertainty. However, results must always be correlated with clinical findings and biochemical markers. A negative result does not exclude all forms of adrenoleukodystrophy, and thorough genetic counseling is essential to interpret carrier status accurately. This test is designed to guide multidisciplinary care and should complement, not replace, your physician's ongoing clinical judgment.โ€

โ€” Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Clinical Advisory & Medication Guidance

Do not alter or discontinue any prescribed medications without first consulting your treating physician. This genetic test provides diagnostic and carrier status information but does not replace ongoing medical management or acute care protocols. Always adhere to your physician's treatment plan and attend scheduled follow-up appointments.

Safety Exclusions & Emergency Red Flags

  • Patients with active acute neurological decompensation or suspected adrenal crisis must seek emergency care immediately; genetic testing is not appropriate during acute episodes.
  • Blood collection is not recommended for individuals with severe coagulopathy or active bleeding disorders.
  • If you develop severe headache, seizure, or altered consciousness, visit the nearest emergency room without delay.
  • This test is not a substitute for newborn screening; for neonatal evaluation, refer to DHA-mandated screening protocols.

Pre-Test Requirement: A prior genetic counseling appointment and a detailed three-generation pedigree chart are mandatory (DHA compliance).

Patient FAQ & Clinical Guidance

1. What is the accuracy of this genetic test for diagnosing X-linked adrenoleukodystrophy?

Using advanced NGS technology, our test achieves 99.9% diagnostic sensitivity for ABCD1 mutations, detecting point mutations, small insertions/deletions, and large copy number variations with clinical-grade precision. This comprehensive coverage ensures reliable results for both affected individuals and carriers.

2. What is the turnaround time and how will I receive my results?

Results are ready within 3โ€“4 weeks from sample receipt. They are securely delivered via a HIPAA-compliant patient portal and accompanied by a telephonic clinical guidance session with a qualified genetic counselor to help interpret findings and discuss next steps.

3. Is this test suitable for children, and what are the legal requirements in the UAE?

Yes, the test is suitable for children with parental consent as mandated by UAE law. Written informed consent from a legal guardian is required, and minors must be accompanied by a guardian during home sample collection. The process fully complies with Federal Decree-Law No. 4 of 2016 on Medical Liability and applicable child protection regulations.

UAE Regulatory & Data Privacy Adherence

Data Protection & Health Information Security

This test operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed within secure UAE-based infrastructure. Patient consent for genetic analysis is obtained and documented in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring autonomous decision-making and confidentiality throughout the testing lifecycle.

DNA Labs UAE maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and adheres to DHA and MOHAP regulatory standards for genetic testing services.

Clinical & Logistical Metadata

Test Name ABCD1 Gene (X-Linked Adrenoleukodystrophy) โ€“ Genetic Test
Price (AED) 2,800 AED
Turnaround Time 3โ€“4 Weeks
Sample Type / Matrix Peripheral Whole Blood (EDTA) โ€“ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AMโ€“11 PM
Methodology Used Next-Generation Sequencing (NGS) โ€“ Full gene coverage with Sanger confirmation of clinically significant variants
ICD-10-CM Code E71.52 (X-linked adrenoleukodystrophy)
LOINC Code 93119-6 (ABCD1 gene mutation analysis in Blood or Tissue by Sequencing)
DHA Facility License & Laboratory Address DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

ุฏุนู… ุซู†ุงุฆูŠ ุงู„ู„ุบุฉ ู…ุชุงุญ

ุงู„ุชุญู‚ู‚ ู…ู† ุงู„ุชุบุทูŠุฉ ุงู„ุชุฃู…ูŠู†ูŠุฉ

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

ุชูˆู‚ู ุนู† ุงู„ุชุฎู…ูŠู†. ุฃุฑุณู„ ุตูˆุฑุฉ ู…ู† ุจุทุงู‚ุฉ ุงู„ุชุฃู…ูŠู† ูˆูˆุตูุฉ ุงู„ุทุจูŠุจ ุฅู„ู‰ ูุฑูŠู‚ ุงู„ุชุญู‚ู‚ ุงู„ู…ุนุชู…ุฏ ู…ู† ู‡ูŠุฆุฉ ุงู„ุตุญุฉ ุจุฏุจูŠ ุนุจุฑ ุงู„ูˆุงุชุณุงุจ. ุงุญุตู„ ุนู„ู‰ ุชุญุฏูŠุซ ุงู„ุญุงู„ุฉ ููŠ ุฏู‚ุงุฆู‚.

โœ… DHA Certified โœ… ISO 15189 โœ… HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

๐Ÿ…

ISMS 27001:2022

๐Ÿ“‹

ISO Accredited

๐Ÿ”’

HIPAA

All reports reviewed by DHA-Certified physicians